The government on Friday said that it is considering a change in the price approval method for new medicines.
The development assumes significance as the current practice causes considerable time delays in the launch of new drugs by manufacturers.
According to the Ministry of Chemicals and Fertilisers, it is in consultation with the industry to explore "doing away with the present practice" of deciding a new price for each applicant of "new drug".
"The government is in consultation with the industry to explore doing away with the present practice of deciding a new price for each applicant of "new drug", which is causing considerable time delay in launch of the new drugs in the market by the manufacturers," the ministry said in a statement.
The ministry also clarified that it is not considering any proposal to change the "methodology of calculating ceiling prices of scheduled medicines".
As per the provisions of DPCO (Drug Price Control Order), prices of those medicines are fixed by the government which are in the National List of Essential Medicines (NLEM).
Currently, NLEM has about 850 drugs against more than 6,000 medicines available in the market of various strengths and dosages.
--IANS
rv/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
